Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Overall Survival in Black Patients Newly Diagnosed With Multiple Myeloma During the Triplet and Quadruplet Therapy Era

  • By

  • Hamlet Gasoyan

  • Shahzad Raza

  • Michael B. Rothberg

  • Jeffrey D. Kovach

  • Nicholas J. Casacchia

  • Jason Valent

  • Faiz Anwer

  • October 7, 2026

Share

  • 1

    This retrospective cohort study assessed overall survival among 1209 Black and White adults newly diagnosed with multiple myeloma at Cleveland Clinic from 2017 through 2023.

  • 2

    Within 1 year of diagnosis, 58.2% of Black patients and 55.9% of White patients received triplet or quadruplet therapy.

  • 3

    After overlap weighting, estimated 5-year overall survival was 59.8% among Black patients and 58.3% among White patients.

  • 4

    In adjusted Cox regression, Black patients had a lower hazard of death than White patients through 5 years (adjusted hazard ratio, 0.73; 95% CI, 0.55-0.97).

  • 5

    A sensitivity analysis limited to patients who received at least 1 multiple myeloma induction medication showed a similar association (adjusted hazard ratio, 0.74; 95% CI, 0.55-1.00).

Original Source(s)

Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies

  • by Hamlet Gasoyan, Shahzad Raza, Michael B. Rothberg, Jeffrey D. Kovach, Nicholas J. Casacchia, Jason Valent, Faiz Anwer

  • October 7, 2026

Related Content

Pulmonary Kaposi Sarcoma Presenting With Flame-Shaped Computed Tomography Opacities in Advanced HIV

  • October 6, 2026

Reading Skin Cancer’s Molecular Fingerprint

Machine-learning models analyzed Raman spectra to distinguish cancerous tissue from normal skin

  • October 6, 2026

  • 2 min
Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)